Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt (MRI)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
BTG International Inc.
ClinicalTrials.gov Identifier:
NCT00442364
First received: February 27, 2007
Last updated: January 7, 2014
Last verified: January 2014
  Purpose

The purpose of this study is to determine the safety of the Varisolve® procedure in patients with right-to-left cardiac shunt (a defect in the heart).


Condition Intervention Phase
Varicose Veins
Drug: Polidocanol (1%) Microfoam (Varisolve)
Procedure: Endovenous Microfoam Occlusion
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Multicenter Safety Study of the Varisolve® Procedure for the Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt

Resource links provided by NLM:


Further study details as provided by BTG International Inc.:

Primary Outcome Measures:
  • Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects [ Time Frame: 28 day followup ] [ Designated as safety issue: Yes ]

Enrollment: 60
Study Start Date: March 2007
Study Completion Date: August 2009
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Polidocanol (1%) Microfoam (Varisolve)
Drug: Polidocanol (1%) Microfoam (Varisolve)
Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
Procedure: Endovenous Microfoam Occlusion
Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.

Detailed Description:

Varicose veins are extremely common, affecting up to 25% of the western adult population. While in their early stages they are little more than a sometimes-painful aesthetic problem, progression is inevitable and some will progress to more severe and largely irreversible problems of chronic venous insufficiency (CVI) and, finally, venous leg ulcer. At present, no system has been proven to identify those that will progress and while varicose veins are not the only cause of CVI, in approximately 50% of patients with leg ulcers, superficial varicose veins are the only causal factor identified. The cost of management of simple varicose veins is relatively small in comparison with the long-term management of CVI and leg ulcers. Many patients progress to develop leg ulcers without having received primary treatment for their varicose veins.

The current management of major varicose veins includes maintenance by compression stockings, injection sclerotherapy with liquid sclerosants, and superficial vein surgery. The disadvantages to surgery include the use of general anesthesia, incisions resulting in possible scars, a painful recovery period with significant functional down time and historically high rates of recurrence. Sclerotherapy has been performed since 1851 with the advent of hypodermic needles. The two surfactant sclerosants most widely used are sodium tetradecyl sulphate (STS, STD®, Sotradecol or Fibro-vein) and polidocanol (Macrogol 400 Ph Eur, Aethoxyskerol®). Sotradecol is the only FDA-approved sclerosant. With the advent of duplex ultrasound scanning, the technique of echo-guided sclerotherapy has widened the possibilities for sclerotherapy of large veins but the liquid sclerosants available are rapidly deactivated and diluted by blood frequently resulting in unsatisfactory outcomes. Because the microfoam delivers sclerosant more efficiently to the venous endothelium, it is believed that lower concentrations of polidocanol (Varisolve)can be used when compared with liquid sclerosant. BTG International Ltd is developing sclerosant microfoam technology based on polidocanol (PD)(Varisolve) into a pharmaceutical product.

The presence of bubbles in the heart has been a concern as bubbles may pass from the right heart to the left through a patent foramen ovale (PFO) or other right-to-left shunt. Once in the systemic circulation, some bubbles inevitably pass into the cerebral circulation where their theoretical potential for causing damage due to occlusion of vessels is recognized yet ill defined.

Therefore this study is to determine whether patients with bubbles detected in the middle cerebral artery (MCA) during the Varisolve® procedure experience any sub-clinical, safety-related events such as abnormalities on brain MRI, neurological examination, cardiac markers or other symptoms or signs.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females aged 18 to 60 with severe varicose veins, CEAP classes 3, 4 and 5 (CEAP is a classification and grading system for chronic venous disease)
  • Saphenofemoral junction (SFJ) incompetence. Retrograde blood flow in the GSV, greater than or equal to 1.0 second demonstrated by duplex scanning.
  • Normal MRI, as assessed on MRI examination performed within 5 days prior to procedure.
  • Patient must be willing and able to participate in the study and provide written informed consent.

Exclusion Criteria:

  • Presence of venous ulcers (i.e. CEAP classification C6) or local infection in the limb to be treated.
  • Incompetence of the small saphenous vein (SSV) in the leg to be treated. Venographic or ultrasonographic evidence of current or previous deep vein thrombosis (DVT) (see Appendix IV).
  • Deep venous occlusion and/or incompetence. Evidence of deep venous reflux is acceptable if it is confined to a limited segment caused by filling of the incompetent superficial system through a perforator or the SFJ.
  • Patients with known atherosclerotic disease or presence of major risk factors, including LDL cholesterol greater than 130 mg/dl, blood pressure greater than 140 mmHg systolic or 90 mmHg diastolic, or diabetes requiring treatment with oral hypoglycemic drugs or insulin.
  • Smokers.
  • History suggestive of cerebral atherosclerosis, transient ischemic attack (TIA), stroke, presence of carotid bruit or history of abnormal carotid duplex examination.
  • Clinically significant dilated cardiomyopathy, evidence of regional wall motion abnormalities suggestive of prior myocardial infarction, rheumatic mitral valve disease, moderately severe or worsening cardiac valvular disease (> 2+ on a scale of 4), known or suspected congenital heart disease, evidence of right sided volume or pressure overload, history of atrial fibrillation. Patients with PFO, atrial septal defect, or other right-to-left shunt are not excluded unless associated with other abnormalities as above.
  • Peripheral vascular disease.
  • Spontaneous emboli seen on TCD prior to contrast injection.
  • Body Mass Index >30.0.
  • Recent or current upper respiratory tract illness or other cause of increased coughing.
  • Arterial insufficiency in the leg to be treated (ankle: brachial pressure ratio less than 0.9).
  • Reduced mobility - unable to maintain a brisk walk unaided for a minimum of 5 minutes per hour per day.
  • Prolonged automobile or air travel (>4 hours) 1 month prior to treatment, or planned within 1 month of proposed treatment.
  • Current or prior pulmonary embolism.
  • Major surgery, prolonged hospitalization or pregnancy within 3 months of screening.
  • Hormone replacement therapy or hormonal contraception (oral or dermal patch).
  • Current or recent (<7 days before treatment) aldehyde dehydrogenase inhibitor therapy, e.g. disulfiram, or other drugs with similar reactions to alcohol (metronidazole, tinidazole).
  • Current anticoagulation therapy.
  • Inability to identify a unilateral or bilateral temporal bone window and middle cerebral artery signal by transcranial Doppler ultrasound.
  • Inability to undergo magnetic resonance imaging of the brain
  • Participation in a clinical study involving an unlicensed pharmaceutical product within the 3 months of screening.
  • Previous enrollment in this study.
  • Major co-existing disease (e.g. malignancy, pulmonary disease, renal or hepatic insufficiency).
  • Known allergic response to polidocanol or severe and multiple allergic reactions.
  • Women of childbearing potential not using effective contraception
  • Pregnant or lactating women.
  • Current alcohol or drug abuse.
  • Clinically significant laboratory abnormalities in the opinion of the investigator.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00442364

Locations
United States, California
Los Angeles, California, United States, 90033
United States, North Carolina
Durham, North Carolina, United States, 27710
Winston-Salem, North Carolina, United States, 27157
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19107
Pittsburgh, Pennsylvania, United States, 15232
United States, Texas
Houston, Texas, United States, 77030
United States, Washington
Bellevue, Washington, United States, 98004
Sponsors and Collaborators
BTG International Inc.
Investigators
Study Director: Janet Rush, MD BTG International Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: BTG International Inc.
ClinicalTrials.gov Identifier: NCT00442364     History of Changes
Other Study ID Numbers: VAP.VV012
Study First Received: February 27, 2007
Results First Received: January 7, 2014
Last Updated: January 7, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by BTG International Inc.:
PFO
Patent Foramen Ovale
Right-to-Left Shunt
Sclerotherapy

Additional relevant MeSH terms:
Varicose Veins
Vascular Diseases
Cardiovascular Diseases
Polidocanol
Sclerosing Solutions
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 14, 2014